Formulations That Meet Unmet Patient Needs
Focused on long acting
Developing Finished Dosage Forms and a Portfolio of APIs
Fully integrated GMP
Pipeline of Multiple Late Stage Products
In Phase III for RMS and Phase II for
PPMS for treating MS
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Our main focus is on developing long acting depot injectable drugs.
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020
90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years Data suggest that GA Depot may also have potential as a primary progressive multiple sclerosis (PPMS) treatment NESS...
Mapi Pharma and Mylan Strengthen Partnership to Develop and Commercialize Once-Monthly Glatiramer Acetate Depot for Relapsing-Remitting Forms of Multiple Sclerosis
NESS ZIONA, Israel, June 15, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced an additional $20 million investment from Mylan in support of continued Phase 3 clinical study progress to bring to market in the U.S. Glatiramer Acetate (GA) Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).